Jason Sandberg, MD
Payments from drug & device makers
Across 120 payments — averaging $100.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8K
- Boston Scientific$1K
- Teleflex LLC$228
- Endo USA, Inc.$164
- Biotissue Holdings Inc.$162
- Coloplast$158
- plus $2K from 26 others
What the payments were for
- Travel & lodging$41912%
- Food & beverage$3,12688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $8,487 |
| Boston Scientific | 20 | $1,104 |
| Teleflex LLC | 5 | $228 |
| Endo USA, Inc. | 6 | $164 |
| Biotissue Holdings Inc. | 2 | $162 |
| Coloplast | 3 | $158 |
| Dendreon Pharmaceuticals LLC | 6 | $152 |
| Myriad Genetic Laboratories, Inc. | 3 | $147 |
| Urogen Pharma, Inc. | 5 | $123 |
| Sumitomo Pharma America, Inc. | 6 | $121 |
| Astellas Pharma US Inc | 7 | $117 |
| AbbVie | 6 | $105 |
| Laborie Medical Technologies Corp. | 1 | $90 |
| Merck | 3 | $87 |
| Olympus America Inc. | 5 | $86 |
| Photocure Inc | 4 | $76 |
| Cook Medical LLC | 4 | $76 |
| Antares Pharma, Inc. | 3 | $62 |
| Bayer | 3 | $57 |
| Progenics Pharmaceuticals, Inc. | 2 | $56 |
| Tolmar, Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $41 |
| Tolmar Pharmaceuticals, Inc. | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| 180 Medical, Inc. | 2 | $31 |
| Verity Pharmaceuticals Inc. | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Calyxo, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ERECTILE DYSFUNCTION$505
- UroLift$137
- TITAN$122
- Prolaris$122
How this compares
$12,032 in reported general payments places this provider in the 80th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 120 | $91,501 |
| GemtesaVibegron | 52 | $57,940 |
| Tamsulosin Hcl | 693 | $12,956 |
| Mirabegron ErMirabegron | 20 | $11,453 |
| Finasteride | 409 | $7,504 |
| Trospium Chloride ErTrospium Chloride | 14 | $4,774 |
| Potassium Citrate ErPotassium Citrate | 35 | $3,245 |
| Methenamine Hippurate | 25 | $2,297 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 72 | $2,176 |
| Oxybutynin Chloride ErOxybutynin Chloride | 61 | $1,629 |
| Dutasteride | 23 | $1,230 |
| Testosterone Cypionate | 22 | $869 |
| CefuroximeCefuroxime Axetil | 74 | $845 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $838 |
| Solifenacin Succinate | 12 | $550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $117 | $91,501120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $121 | $57,94052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 urology providers in Michigan.
Other urology in Troy
- Kenneth KernenTroy$3.4M
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
- Khurshid GhaniAnn Arbor$550K
- Richard BennettRoyal Oak$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.